TC
EPZM

TFS Capital’s Epizyme, Inc EPZM Stock Holding History

TFS Capital’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-10,330
Closed -$125K – 916
2016
Q4 		$125K Sell
10,330
-9,083
-47% -$94.8K 0.03% 608
2016
Q3 		$191K Sell
19,413
-120,035
-86% -$1.1M 0.05% 569
2016
Q2 		$1.43M Buy
139,448
+559
+0.4% +$6.23K 0.26% 81
2016
Q1 		$1.68M Buy
138,889
+64,189
+86% +$649K 0.24% 106
2015
Q4 		$1.2M Buy
+74,700
New +$1.11M 0.13% 273
2015
Q2 		– Sell
-14,247
Closed -$268K – 1144
2015
Q1 		$268K Sell
14,247
-18,861
-57% -$389K 0.03% 720
2014
Q4 		$625K Buy
33,108
+17,503
+112% +$409K 0.06% 516
2014
Q3 		$423K Buy
+15,605
New +$485K 0.04% 646
2014
Q2 		– Sell
-14,195
Closed -$323K – 1424
2014
Q1 		$323K Buy
+14,195
New +$430K 0.02% 975
2013
Q4 		– Sell
-9,991
Closed -$400K – 1693
2013
Q3 		$400K Buy
+9,991
New +$338K 0.02% 980

Other funds holding EPZM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

TFS Capital's EPZM Position: Q1 2017 in Review

TFS Capital sold out of Epizyme, Inc (EPZM) in Q1 2017, closing a stake of 10,330 shares — an estimated $125K sold.

TFS Capital first reported a position in EPZM in Q3 2013 and held it in 10 quarters. The position peaked at $1.68M in Q1 2016. 95 funds tracked by Wall St. Rank hold EPZM as of Q1 2017.

  • TFS Capital reported no remaining Epizyme, Inc position as of Q1 2017 after selling out during the quarter.
  • TFS Capital sold 10,330 Epizyme, Inc shares in Q1 2017, an estimated $125K.
  • TFS Capital first reported a position in Epizyme, Inc in Q3 2013 and held it in 10 quarters.
  • TFS Capital's Epizyme, Inc position peaked at $1.68M in Q1 2016.
  • 95 funds tracked by Wall St. Rank held Epizyme, Inc as of Q1 2017.

Based on TFS Capital's 13F filing for Q1 2017, filed 5 May 2017.